ARYx Therapeutics, Inc.
ARYX · OTC
12/31/2009 | 12/31/2008 | 12/31/2007 | 12/31/2006 | |
|---|---|---|---|---|
| Revenue | $0 | $19,724 | $4,158 | $4,739 |
| % Growth | -100% | 374.4% | -12.3% | – |
| Cost of Goods Sold | $0 | $232 | $262 | $2,116 |
| Gross Profit | $0 | $19,492 | $3,896 | $2,623 |
| % Margin | – | 98.8% | 93.7% | 55.3% |
| R&D Expenses | $21,040 | $40,145 | $24,994 | $23,973 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $10,198 | $9,764 | $7,702 | $6,938 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $31,238 | $49,909 | $32,696 | $30,911 |
| Operating Income | -$31,238 | -$30,417 | -$28,800 | -$28,288 |
| % Margin | – | -154.2% | -692.6% | -596.9% |
| Other Income/Exp. Net | -$1,929 | -$801 | $1,239 | $970 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $849 | $801 | -$1,239 | -$960 |
| Net Income | -$33,167 | -$31,218 | -$27,561 | -$27,328 |
| % Margin | – | -158.3% | -662.8% | -576.7% |
| EPS | -1.21 | -1.65 | -2.93 | -26.84 |
| % Growth | 26.7% | 43.7% | 89.1% | – |
| EPS Diluted | -1.21 | -1.65 | -2.93 | -26.84 |
| Weighted Avg Shares Out | 27,438 | 18,964 | 9,406 | 1,018 |
| Weighted Avg Shares Out Dil | 27,438 | 18,964 | 9,406 | 1,018 |
| Supplemental Information | – | – | – | – |
| Interest Income | $78 | $1,127 | $2,591 | $2,294 |
| Interest Expense | $2,007 | $1,928 | $1,352 | $1,324 |
| Depreciation & Amortization | $1,080 | $1,463 | $1,238 | $920 |
| EBITDA | -$30,060 | -$29,320 | -$27,562 | -$27,368 |
| % Margin | – | -148.7% | -662.9% | -577.5% |